NCT06815029 2025-06-26
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
City of Hope Medical Center
Phase 1 Recruiting
Clinical Trials
6 trialsNCT03696030 2025-04-13
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02100891 2025-03-19
STIR
Medical College of Wisconsin
Phase 2 Terminated
NCT02664363 2023-02-17
ExCeL
Duke University
Phase 1 Terminated
NCT03423992 2021-06-15
Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas
Xuanwu Hospital, Beijing
Phase 1 Unknown
NCT02575261 2020-07-16
CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Withdrawn